Federal Register of Legislation - Australian Government

Primary content

PB 24 of 2021 Determinations/Health as made
This instrument amends the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019) to add listed pharmaceutical items which must be supplied as complete packs only.
Administered by: Health
Registered 31 Mar 2021

PB 24 of 2021

 

National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 2)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under paragraph 98C(1) of the National Health Act 1953.

Dated         31 March 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2021 (No. 2).

(2)          This Instrument may also be cited as PB 24 of 2021.

2          Commencement

This Instrument commences on 1 April 2021.

3          Amendments to National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019

Schedule 1 amends the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019.

 

 

                     


Schedule 1     Amendments

[1]        Schedule 4, entry for Cefuroxime

omit:

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL